Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Solon Eiendom ASA : Primary insider notification

Solon Eiendom ASA
Posted on: 11 Apr 18

(Oslo, Norway, July 4, 2018)  UFI AS has today bought 19 791 shares in Solon Eiendom ASA at a price of NOK 30.06 per share. Solon Eiendom ASA Board Member Øystein A. Landvik owns 33,34 % of the shares in UFI AS.

Following this transaction UFI AS holds 3 015 527 shares in Solon Eiendom ASA. UFI AS further holds a TRS agreement with underlying exposure to 2 385 808 shares for a total holding of 5 401 335 shares, equaling 9,556 % of the total share capital and votes of the Company.

This information is subject to the disclosure requirements set out in section 5-12 of the Norwegian Securities Trading Act.

Further information
Andreas Martinussen
Chief Executive Officer, Solon Eiendom ASA
E-mail: Cell Phone: +47 400 00 405

Scott Danielsen
Chief Financial Officer, Solon Eiendom ASA
E-mail: Cell Phone: +47 952 55 620

About Solon Eiendom
Solon Eiendom is a Norwegian residential real estate development company focusing on the Oslo and Akershus region.


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Solon Eiendom ASA via GlobeNewswire

Last updated on: 05/07/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.